Navigation Links
Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer
Date:8/22/2014

LA JOLLA, Cali., Aug. 22, 2014 /PRNewswire/ -- Research presented at the 29th Annual International Papillomavirus Conference shows that a therapy being developed by Hera Therapeutics Inc. combats three types of human papillomavirus, including the two that cause 70 percent of all cervical cancer.

When tested in several cultured human cell models, HTI-1968 blocked the replication of HPV-16, HPV-18 and HPV-11 cells, according to Louise T. Chow, Ph.D. and Thomas Broker, Ph.D., who presented the findings at the Seattle conference. The National Institute of Allergy and Infectious Diseases in the National Institutes of Health funded Chow's work at the University of Alabama, Birmingham.

"HTI-1968 is potent and selective, inhibiting the growth of these high-risk HPV types. Dr. Chow's findings, though early stage, offer hope to millions of women infected by one of these high-risk HPV types, including two that are responsible for 70 percent of cervical cancer cases," said Hera Therapeutics CEO Karl Hostetler, M.D.. Currently surgery is the only therapy available to women who have persistent infection with these types of HPV and show signs of abnormal cells.

Hera Therapeutics is developing a topical, non-surgical approach to treat HPV, which could alter the standard of care while preserving structural integrity of the cervix.

Approximately 96 million people worldwide, men and women, are infected with HPV-16 or HPV-18, according to the Centers for Disease Control. Almost 4,000 women in the U.S. die from invasive cervical cancer each year, according to the CDC.

While cervical cancer vaccines prevent infection from the disease, they are not approved by the FDA for marketing to people over 26-years-old and have not demonstrated efficacy in people already infected with the HPV virus.

About Hera Therapeutics Inc.

Using a new medicinal chemistry platform, Hera Therapeutics Inc. is focused on the research, development and commercialization of direct acting antivirals for infections with the human papillomavirus, herpes group viruses, HIV and animal retroviruses.

Hera Therapeutics was founded in 2012 by Karl Hostetler, M.D., a professor emeritus at University of California, San Diego, who was previously a founder of three biotech companies, including Chimerix, Triangle Pharmaceuticals and Vical.


'/>"/>
SOURCE Hera Therapeutics Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients
2. Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite
3. Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting
4. Coherus Announces CHS-1420 (Investigational Adalimumab Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
5. FDA Accepts CorMedix, Inc. Pivotal Phase 3 Study Protocol
6. TRU-D Tested in Most Comprehensive UV Disinfection Study to Date
7. Major Clinical Study Supports NIPT As First Line Screening Test For All Pregnant Women
8. R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study
9. Study: 1 out of 5 adult orthopaedic trauma patients sought additional providers for narcotic prescriptions
10. Study Helps Medical Education Leaders Navigate the New Regulatory and Financial Landscape
11. BioSpecifics Technologies Corp. Announces Initiation of Phase 2 Clinical Study of CCH for Treatment of Lipoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... Mar 01, 2017 ... Research and Markets has announced ... to 2017" report to their offering. The ... report provides understanding and access to partnering deals and agreements entered ... provides an analysis of partnering deals. The majority of deals are ...
(Date:3/1/2017)... Research and Markets has announced the addition of the ... to their offering. ... This analysis is one of the most accurate studies performed ... financial data derived from varied research sources to present unique and ... market during the next five years, including a deep dive analysis ...
(Date:3/1/2017)... , March 1, 2017  Numotion, the nation,s leading ... availability of Tek RMD ("robotic mobilization device") by Matia ... Tek RMD is a motorized standing movement device that ... manual wheelchair to complete everyday activities from a standing ... a Tek RMD unassisted. Numotion is the exclusive distributor ...
Breaking Medicine Technology:
(Date:3/1/2017)... ... March 01, 2017 , ... After a long period of ... cleanse. While juice cleanses and workouts top the detox categories, there is a rare ... regime. The Kerry Gaynor Method’s Vital Lung Detox is an herbal-based formula designed to ...
(Date:3/1/2017)... ... March 01, 2017 , ... Look for a new collection ... Roses and Drift Roses. Star Roses and Plants is launching their new Bushel ... The Bushel and Berry Collection makes growing fresh fruit simple with a variety of ...
(Date:3/1/2017)... ... March 01, 2017 , ... Breast Surgeon, Dr. Dennis Holmes of 90210 ... breast cancer and where it fits in the treatment paradigm at Susan G. Komen ... The event brings together leading cancer and wellness experts to share the latest innovations ...
(Date:3/1/2017)... ... March 01, 2017 , ... Granite Peaks Gastroenterology recently announced ... by supporting the 80% by 2018 initiative, led by the American Cancer Society ... Cancer Roundtable (an organization co-founded by ACS and CDC). , “80% by 2018” ...
(Date:3/1/2017)... ... 2017 , ... “There is Comfort for the Soul”: a loving account of ... all-too-brief time together, and the soul-healing comfort provided by God’s presence in the face ... author, Jerie A. Tau, a dog-loving medical professional whose work takes her to remote ...
Breaking Medicine News(10 mins):